-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 19, Shanghai Pharmaceuticals issued an announcement stating that the clinical trial application for the development of "SPH3127 tablets" for chronic kidney disease indications was officially accepted by the State Food and Drug Administration.
SPH3127 tablets are a new type of oral renin inhibitor.
This drug application intends to carry out clinical trials with chronic kidney disease as the indication.
Up to now, the project has invested a total of RMB 7.